Search

Your search keyword '"Korhonen, Maarit"' showing total 426 results
Start Over Author "Korhonen, Maarit"
426 results on '"Korhonen, Maarit"'

25. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ogundipe, Oyepeju, Mazidi, Mohsen, Chin, Ken Lee, Gor, Deval, McGovern, Andrew, Sahle, Berhe W., Jermendy, György, Korhonen, Maarit Jaana, Appiah, Bernard, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny, Ofori-Asenso, Richard, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ogundipe, Oyepeju, Mazidi, Mohsen, Chin, Ken Lee, Gor, Deval, McGovern, Andrew, Sahle, Berhe W., Jermendy, György, Korhonen, Maarit Jaana, Appiah, Bernard, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny, and Ofori-Asenso, Richard

Published
2021

26. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors:a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes

Author

Ogundipe, Oyepeju, Mazidi, Mohsen, Chin, Ken Lee, Gor, Deval, McGovern, Andrew, Sahle, Berhe W., Jermendy, György, Korhonen, Maarit Jaana, Appiah, Bernard, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny, Ofori-Asenso, Richard, Ogundipe, Oyepeju, Mazidi, Mohsen, Chin, Ken Lee, Gor, Deval, McGovern, Andrew, Sahle, Berhe W., Jermendy, György, Korhonen, Maarit Jaana, Appiah, Bernard, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny, and Ofori-Asenso, Richard

Abstract

Aims: Medication adherence and persistence are important determinants of treatment success in type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis evaluated the real-world adherence, persistence, and in-class switching among patients with T2DM prescribed dipeptidyl peptidase-4 (DPP4) inhibitors. Methods: MEDLINE, EMBASE, Cochrane Library, PsychINFO, and CINAHL were searched for relevant observational studies published in the English language up to 20 December 2019. This was supplemented by manual screening of the references of included papers. Random-effects meta-analysis was performed. Results: Thirty-four cohort studies involving 594,138 patients with T2DM prescribed DPP4 inhibitors from ten countries were included. The pooled proportion adherent (proportion of days covered (PDC) or medication possession ratio (MPR) ≥ 0.80) was 56.9% (95% confidence interval [CI] 49.3–64.4) at one year and 44.2% (95% CI 36.4–52.1) at two years. The proportion persistent with treatment decreased from 75.6% (95% CI 71.5–79.5) at six months to 52.8% (95% CI 51.6–59.8) at two years. No significant differences in adherence and persistence were observed between individual DPP4 inhibitors. At one year, just 3.2% (95% CI 3.1–3.3) of patients switched from one DPP4 inhibitor to another. Switching from saxagliptin and alogliptin to others was commonest. Conclusions: Adherence to and persistence with DPP4 inhibitors is suboptimal but similar across all medications within the class. While in-class switching is uncommon, saxagliptin and alogliptin are the DPP4 inhibitors most commonly switched. Interventions to improve treatment adherence and persistence among patients with T2DM prescribed DPP4 inhibitors may be warranted.

Published
2021

32. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities

Author

Halava, Heli, Korhonen, Maarit Jaana, Huupponen, Risto, Setoguchi, Soko, Pentti, Jaana, Kivimaki, Mika, and Vahtera, Jussi

Subjects
Patient compliance -- Evaluation, Life style -- Evaluation, Cardiovascular diseases -- Care and treatment, Health
Abstract

Background: Easily detectable predictors of nonadherence to long-term drug treatment are lacking. We investigated the association between lifestyle factors and nonadherence to statin therapy among patients with and without cardiovascular comorbidities. Methods: We included 9285 participants from the Finnish Public Sector Study who began statin therapy after completing the survey. We linked their survey data with data in national health registers. We used prescription dispensing data to determine participants' nonadherence to statin therapy during the first year of treatment (defined as < 80% of days covered by filled prescriptions). We used logistic regression to estimate the association of several lifestyle factors with nonadherence, after adjusting for sex, age and year of statin initiation. Results: Of the participants without cardiovascular comorbidities (n = 6458), 3171 (49.1%) were nonadherent with their statin therapy. Obesity (adjusted odds ratio [OR] 0.86, 95% confidence interval [CI] 0.74-0.99), overweight (adjusted OR 0.88, 95% CI 0.79-0.98) and former smoking (adjusted OR 0.82, 95% CI 0.74-0.92) predicted a reduced risk of nonadherence in this group after adjustment for sex, age and year of statin initiation. Of the participants with cardiovascular comorbidities (n = 2827), 1155 (40.9%) were nonadherent. In this group, high alcohol consumption (adjusted OR 1.55, 95% CI 1.12-2.15), extreme drinking occasions (adjusted OR 1.48, 95% CI 1.11-1.97) and a cluster of 3-4 lifestyle risks (adjusted OR 1.61, 95% CI 1.15-2.27) predicted increased odds of nonadherence after adjustment for sex, age and year of statin initiation. Interpretation: People with cardiovascular comorbidities who had risky drinking behaviours or a cluster of lifestyle risks were at increased risk of nonadherence. Among individuals without cardiovascular comorbidities, information on lifestyle factors was unhelpful in identifying those at increased risk of nonadherence; that overweight, obesity and former smoking were predictors of better adherence in this group provides insight into mechanisms of adherence to preventive medication that deserve further study., A recent meta-analysis of 44 epidemiologic studies suggested that almost 1 in 10 cardiovascular events can be attributed to medication nonadherence. (1) For statins, the average prevalence of nonadherence, defined [...]

Published
2014
Full Text
View/download PDF

33. Odor annoyance near waste treatment centers: a population-based study in Finland

Author

Aatamila, Marjaleena, Verkasalo, Pia K., Korhonen, Maarit J., Viluksela, Marja K., Pasanen, Kari, Tiittanen, Pekka, and Nevalainen, Aino

Subjects
Stimulus satiation -- Research, Stimulus intensity -- Research, Odors -- Research, Environmental services industry, Environmental issues, Science and technology
Abstract

ABSTRACT Decomposition of biodegradable waste in municipal waste centers may produce odor emissions and subsequently cause discomfort to nearby residents. The public health importance of the resulting nuisance has not [...]

Published
2010
Full Text
View/download PDF

47. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes

Author

Ogundipe, Oyepeju, primary, Mazidi, Mohsen, additional, Chin, Ken Lee, additional, Gor, Deval, additional, McGovern, Andrew, additional, Sahle, Berhe W., additional, Jermendy, György, additional, Korhonen, Maarit Jaana, additional, Appiah, Bernard, additional, Ademi, Zanfina, additional, De Bruin, Marie Louise, additional, Liew, Danny, additional, and Ofori-Asenso, Richard, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results